Swiss Medical Weekly (Jun 2024)

Bone health in patients with inflammatory bowel disease

  • Andrea Kreienbuehl,
  • Gerhard Rogler,
  • Burri Emanuel,
  • Luc Biedermann,
  • Christian Meier,
  • Pascal Juillerat,
  • Sophie Restellini,
  • Peter Hruz,
  • Stefan R. Vavricka,
  • Daniel Aeberli,
  • Frank Seibold

DOI
https://doi.org/10.57187/s.3407
Journal volume & issue
Vol. 154, no. 6

Abstract

Read online

Patients with inflammatory bowel disease (IBD) are prone to reduced bone mineral density and elevated overall fracture risk. Osteopenia affects up to 40% of patients with IBD (high regional variability). Besides disease activity, IBD specialists must consider possible side effects of medication and the presence of associated diseases and extraintestinal manifestations. Osteopenia and osteoporosis remain frequent problems in patients with IBD and are often underestimated because of widely differing screening and treatment practices. Malnutrition, chronic intestinal inflammation and corticosteroid intake are the major pathophysiological factors contributing to osteoporosis. Patients with IBD are screened for osteoporosis using dual-energy X-ray absorptiometry (DXA), which is recommended for all patients with a prolonged disease course of more than three months, with repeated corticosteroid administration, aged >40 years with a high FRAX risk score or aged <40 years with multiple risk factors. From a therapeutic perspective, besides good disease control, vitamin D supplementation and glucocorticoid sparing, several specific osteological options are available: bisphosphonates, receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors (denosumab), parathyroid hormone (PTH) analogues and selective estrogen receptor modulators. This review provides an overview of the pathophysiology, diagnosis, prevention and treatment of IBD-associated bone loss.